Exposure of critical groups to nuclear medicine patients.

[1]  J. Cormack,et al.  Calculation of radiation exposures from patients to whom radioactive materials have been administered. , 1998, Physics in medicine and biology.

[2]  C. R. Edwards,et al.  The response of a MOSFET, p-type semiconductor and LiF TLD to quasi-monoenergetic x-rays. , 1997, Physics in medicine and biology.

[3]  R. Marchesini,et al.  Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose , 1997, European Journal of Nuclear Medicine.

[4]  S. Barrington,et al.  Are all ecological studies fallacious? Not necessarily. , 1997 .

[5]  H. Bergmann,et al.  Radiation doses deriving from patients undergoing 111In-DTPA-d-Phe-1-octreotide scintigraphy , 1997, European Journal of Nuclear Medicine.

[6]  W. Thomson,et al.  Radiological protection and safety in medicine - ICRP 73. , 1997, European journal of nuclear medicine.

[7]  J. Farwell,et al.  An estimate of the maximal doses incurred by persons accompanying patients in the waiting area of a nuclear medicine department , 1997 .

[8]  P. Mountford.  Risk assessment of the nuclear medicine patient. , 1997, The British journal of radiology.

[9]  L K Harding,et al.  Are MIBI/tetrofosmin heart studies a potential radiation hazard to technologists? , 1997, Nuclear medicine communications.

[10]  L. K. Harding,et al.  39. Comparative study of doses to a fellow passenger seated next to myocardial scintigraphy and radioiodine therapy patients , 1997 .

[11]  L. K. Harding,et al.  Posters 1. Dose rates from 131I thyrotoxic patients , 1996 .

[12]  M. O'Doherty,et al.  Radiation protection issues. , 1996, Nuclear medicine communications.

[13]  Hilditch Te,et al.  Radiation protection issues associated with nuclear medicine out-patients. , 1996 .

[14]  S. Barrington,et al.  65. Radiation protection advice after radioiodine therapy -an easier way! , 1996 .

[15]  L. K. Harding,et al.  63. RCP guidelines on radiation protection following radio-iodine therapy for thyrotoxicosis: Are they appropriate? , 1996 .

[16]  L. K. Harding,et al.  64. Use of public transport by 131I therapy outpatients , 1996 .

[17]  D. Bradley,et al.  Variation of relative dose rate with distance from extended sources of 99Tcm , 1996 .

[18]  MJ O'Doherty,et al.  Responsibilities and Protection in the Use of Radioiodine , 1996, Journal of the Royal College of Physicians of London.

[19]  L. K. Harding,et al.  Radiation protection issues associated with nuclear medicine out‐patients , 1995, Nuclear medicine communications.

[20]  K. Faulkner,et al.  Personal monitoring of pregnant staff in diagnostic radiology , 1993 .

[21]  J. Klopper,et al.  Analysis of radiation doses received by the public from 131I treatment of thyrotoxic outpatients. , 1993, Nuclear medicine communications.

[22]  H. Dworkin,et al.  Comparison of personnel radiation dosimetry from myocardial perfusion scintigraphy: technetium-99m-sestamibi versus thallium-201. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Shield Ra,et al.  UK nuclear medicine survey, 1989/90. , 1993 .

[24]  L. K. Harding,et al.  70. Day and night radiation doses to patients?? relatives: implications of ICRP 60 , 1993 .

[25]  S. Barrington,et al.  8. Twenty-four hour discharge for thyroid cancer patients treated with radioiodine , 1993 .

[26]  M. O'Doherty,et al.  Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis , 1993, Nuclear medicine communications.

[27]  M. O'Doherty,et al.  Patient guidance after 131I therapy , 1992, The Lancet.

[28]  G. Akansel,et al.  Iodine-131 contamination from thyroid cancer patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  K. Kearfott,et al.  Radiation protection design for a clinical positron emission tomography imaging suite. , 1992, Health physics.

[30]  L. K. Harding,et al.  Radiation doses from nuclear medicine patients to an imaging technologist: relation to ICRP recommendations for pregnant workers. , 1992, Nuclear medicine communications.

[31]  W. Alexander,et al.  Patient guidance after 131I therapy: time for change? , 1992, The Lancet.

[32]  H. Dworkin,et al.  Radiation safety considerations for post-iodine-131 thyroid cancer therapy. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  M. O'Doherty,et al.  Radiation dose rates from adult patients undergoing nuclear medicine investigations , 1991, Nuclear medicine communications.

[34]  L. K. Harding,et al.  Radiation dose rates from paediatric patients under going 99Tcm investigations , 1991, Nuclear medicine communications.

[35]  R. Shields.  The Guidance Notes revisited: advice to patients leaving hospital after diagnostic nuclear medicine. , 1991, British Journal of Radiology.

[36]  M. Velchik.  Radiation exposure associated with the performance of radiologic studies in radioactive patients , 1990 .

[37]  M. Prescott,et al.  Excretion of iodine-123-hippuran, technetium-99m-red blood cells, and technetium-99m-macroaggregated albumin into breast milk. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  L. K. Harding,et al.  Staff radiation doses associated with nuclear medicine procedures - a review of some recent measurements , 1990, Nuclear medicine communications.

[39]  L. K. Harding,et al.  The radiation dose to accompanying nurses, relatives and other patients in a nuclear medicine department waiting room , 1990, Nuclear medicine communications.

[40]  J. Brameld,et al.  Indium-111 in breast milk following administration of indium-111-labeled leukocytes. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Gandsman Ej,et al.  Intercomparison of film badge and pocket dosimeters for use in nuclear medicine. , 1988 .

[42]  L. K. Harding,et al.  Nuclear medicine and clinical chemistry departments. , 1987, Nuclear medicine communications.

[43]  R. Heap,et al.  Suppression by perchlorate of technetium-99m and iodine-123 secretion in milk of lactating goats. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  R. Sloboda,et al.  Technologist Radiation Exposures from Nuclear Medicine Imaging Procedures , 1987 .

[45]  P. Mountford,et al.  The radiation dose to an infant following maternal radiopharmaceutical administration. , 1986, The British journal of radiology.

[46]  R. Beh,et al.  Iodine 131 Therapy Patients: Radiation Dose to Staff , 1986 .

[47]  C. Hoefnagel,et al.  Radiation protection during treatment of children with 131I-meta-iodobenzylguanidine. , 1986, Health physics.

[48]  C. Richmond.  ICRP publication 23 , 1986 .

[49]  S. Mattsson,et al.  Excretion of radionuclides in human breast milk after the administration of radiopharmaceuticals. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  L. K. Harding,et al.  Dose rates from patients having nuclear medicine investigations , 1985, Nuclear medicine communications.

[51]  B. Wall,et al.  The suitability of different preparations of thermoluminescent lithium borate for medical dosimetry. , 1982, Physics in medicine and biology.

[52]  R. Miller,et al.  Radiation exposure to nursing personnel from patients receiving diagnostic radionuclides. , 1982, Heart & lung : the journal of critical care.

[53]  K. Nishizawa,et al.  Monitoring of I excretions and used materials of patients treated with 131I. , 1980, Health physics.

[54]  T. Shawker,et al.  Potential hazard to ultrasonographers from previously administered radionuclides. , 1980, Radiology.

[55]  B. Heaton.  The build up of technetium in breast milk following the administration of 99Tc(m)O4 labelled macroaggregated albumin. , 1979, The British journal of radiology.

[56]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[57]  P. Plato,et al.  Contamination of the home environment by patients treated with Iodine-131: initial results. , 1978, American journal of public health.

[58]  H. Crompton,et al.  The Aberdeen formula. , 1976, Nursing times.

[59]  R. P. Parker,et al.  Radiation doses to staff in a department of nuclear medicine. , 1976, The British journal of radiology.

[60]  E. Hall,et al.  The Hidden Dimension , 1970 .

[61]  H. Dworkin,et al.  Radiation safety considerations for post-iodine-131 hyperthyroid therapy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  Icrp.  1990 Recommendations of the International Commission on Radiological Protection , 1991 .

[63]  P. Mountford,et al.  A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. , 1989, Nuclear medicine communications.

[64]  P. Mountford,et al.  Body surface dosimetry following re-injection of 111In-leucocytes. , 1989, Nuclear medicine communications.

[65]  P. Mountford.  Estimation of close contact doses to young infants from surface dose rates on radioactive adults. , 1987, Nuclear medicine communications.

[66]  J. Brindle,et al.  Radioiodine therapy to out-patients--the radiation hazard. , 1971, The British journal of radiology.